Literature DB >> 11124804

Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.

P D Jeffrey1, L Tong, N P Pavletich.   

Abstract

The cyclin-dependent kinases 4 and 6 (Cdk4/6) that drive progression through the G(1) phase of the cell cycle play a central role in the control of cell proliferation, and CDK deregulation is a frequent event in cancer. Cdk4/6 are regulated by the D-type cyclins, which bind to CDKs and activate the kinase, and by the INK4 family of inhibitors. INK4 proteins can bind both monomeric CDK, preventing its association with a cyclin, and also the CDK-cyclin complex, forming an inactive ternary complex. In vivo, binary INK4-Cdk4/6 complexes are more abundant than ternary INK4-Cdk4/6-cyclinD complexes, and it has been suggested that INK4 binding may lead to the eventual dissociation of the cyclin. Here we present the 2.9-A crystal structure of the inactive ternary complex between Cdk6, the INK4 inhibitor p18(INK4c), and a D-type viral cyclin. The structure reveals that p18(INK4c) inhibits the CDK-cyclin complex by distorting the ATP binding site and misaligning catalytic residues. p18(INK4c) also distorts the cyclin-binding site, with the cyclin remaining bound at an interface that is substantially reduced in size. These observations support the model that INK4 binding weakens the cyclin's affinity for the CDK. This structure also provides insights into the specificity of the D-type cyclins for Cdk4/6.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124804      PMCID: PMC317144          DOI: 10.1101/gad.851100

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  39 in total

1.  Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin.

Authors:  M Li; H Lee; D W Yoon; J C Albrecht; B Fleckenstein; F Neipel; J U Jung
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.

Authors:  L Zuo; J Weger; Q Yang; A M Goldstein; M A Tucker; G J Walker; N Hayward; N C Dracopoli
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

Review 3.  G1 phase progression: cycling on cue.

Authors:  C J Sherr
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

4.  Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4.

Authors:  L Stepanova; X Leng; S B Parker; J W Harper
Journal:  Genes Dev       Date:  1996-06-15       Impact factor: 11.361

5.  Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.

Authors:  B B McConnell; F J Gregory; F J Stott; E Hara; G Peters
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins.

Authors:  M Hall; S Bates; G Peters
Journal:  Oncogene       Date:  1995-10-19       Impact factor: 9.867

Review 7.  The cell cycle kinases.

Authors:  J Pines
Journal:  Semin Cancer Biol       Date:  1994-08       Impact factor: 15.707

8.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

9.  Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d.

Authors:  D H Brotherton; V Dhanaraj; S Wick; L Brizuela; P J Domaille; E Volyanik; X Xu; E Parisini; B O Smith; S J Archer; M Serrano; S L Brenner; T L Blundell; E D Laue
Journal:  Nature       Date:  1998-09-17       Impact factor: 49.962

10.  Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.

Authors:  D Parry; S Bates; D J Mann; G Peters
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

View more
  54 in total

1.  CAK-independent activation of CDK6 by a viral cyclin.

Authors:  P Kaldis; P M Ojala; L Tong; T P Mäkelä; M J Solomon
Journal:  Mol Biol Cell       Date:  2001-12       Impact factor: 4.138

2.  Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen prolongs the life span of primary human umbilical vein endothelial cells.

Authors:  Takahiro Watanabe; Makoto Sugaya; April M Atkins; Elisabeth A Aquilino; Aparche Yang; Debra L Borris; John Brady; Andrew Blauvelt
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

3.  Identification of a novel Mcl-1 protein binding motif.

Authors:  William J Placzek; Mattia Sturlese; Bainan Wu; Jason F Cellitti; Jun Wei; Maurizio Pellecchia
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

4.  Weak conservation of structural features in the interfaces of homologous transient protein-protein complexes.

Authors:  Govindarajan Sudha; Prashant Singh; Lakshmipuram S Swapna; Narayanaswamy Srinivasan
Journal:  Protein Sci       Date:  2015-09-08       Impact factor: 6.725

Review 5.  CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation.

Authors:  A-S Tigan; F Bellutti; K Kollmann; G Tebb; V Sexl
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

Review 6.  Targeting CDK6 in cancer: State of the art and new insights.

Authors:  Solomon Tadesse; Mingfeng Yu; Malika Kumarasiri; Bich Thuy Le; Shudong Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases.

Authors:  Kazuya Terasawa; Katsuhiko Yoshimatsu; Shun-Ichiro Iemura; Tohru Natsume; Keiji Tanaka; Yasufumi Minami
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

8.  The structure of CDK4/cyclin D3 has implications for models of CDK activation.

Authors:  T Takaki; A Echalier; N R Brown; T Hunt; J A Endicott; M E M Noble
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 9.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

10.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states.

Authors:  Sunita K Agarwal; Carmen M Mateo; Stephen J Marx
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.